Renaissance Capital logo

EXDX News

It's not lupus: Exagen Diagnostics files for a $69 million IPO

EXDX

Exagen Diagnostics, which sells diagnostic blood tests that detect lupus and rheumatoid arthritis, filed on Friday with the SEC to raise up to $69 million in an initial public offering. Primary shareholders include Sun Mountain Capital, Tullis Health Investors, Joseph Advisory Services, Signal Peak Ventures and Capital Royalty. The Vista, CA-based company, which was...read more

Archived Headlines